Product image of Juzina (Sitagliptin Hydrochloride Monohydrate) supplied by GNH India

Juzina

Active Ingredient:
Sitagliptin Hydrochloride Monohydrate
Origin:
EU

Juzina (Sitagliptin Hydrochloride Monohydrate)

Sitagliptin Hydrochloride Monohydrate, the active ingredient in Juzina, is a DPP‑4 inhibitor presented as an oral dosage form for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to improve glycaemic control when used with diet and exercise.

GNH India supplies Juzina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, including regulatory support and temperature‑controlled shipping where required.

Manufacturer / TM Owner

Gedeon Richter România S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Juzina (sitagliptin) is used to improve glycaemic control in the type 2 diabetes therapeutic pathway.

  • Type 2 diabetes mellitus (monotherapy): lowers HbA1c and fasting plasma glucose when used alone with diet and exercise.
  • Type 2 diabetes mellitus (combination therapy): enhances glucose control when added to metformin or other antidiabetic agents.
  • Type 2 diabetes mellitus (renal impairment): provides glycaemic management with dose adjustment in patients with reduced kidney function.

How It Works

  • Sitagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which degrades the incretin hormones GLP‑1 and GIP. By blocking DPP‑4, sitagliptin increases endogenous incretin levels, leading to glucose‑dependent stimulation of insulin secretion and suppression of glucagon release, thereby reducing post‑prandial and fasting blood glucose concentrations without causing hypoglycaemia in the absence of other glucose‑lowering agents.

Side Effects

Like all medications, Juzina may cause adverse reactions, which are classified by frequency and severity.

Common Side Effects

  • Nausea: mild to moderate upset stomach.
  • Headache: transient cranial discomfort.
  • Nasopharyngitis: cold‑like symptoms.
  • Upper respiratory tract infection: mild cough or sore throat.
  • Dizziness: occasional light‑headedness.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring medical attention.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Stevens‑Johnson syndrome: serious skin eruption.
  • Hepatic dysfunction: elevated liver enzymes or hepatitis.
  • Hypoglycaemia: when combined with insulin or sulfonylureas.

Precautions & Warnings

Before initiating Juzina, clinicians should evaluate several safety considerations to minimise risk.

  • Renal function: assess baseline creatinine clearance and adjust dose in impairment.
  • Hepatic function: monitor liver enzymes in patients with liver disease.
  • Cardiovascular disease: use with caution in patients with unstable heart conditions.
  • Elderly patients: consider lower starting dose due to potential decreased clearance.
  • Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks.
  • Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Avoid Interactions

Juzina can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Insulin: concurrent use may increase risk of hypoglycaemia.
  • Sulfonylureas: combined therapy can potentiate hypoglycaemic episodes.

Moderate Interactions (Monitor Closely)

  • Rifampin: enzyme induction may reduce sitagliptin plasma concentrations.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sitagliptin exposure.
  • Diuretics (e.g., thiazides): may diminish glucose‑lowering effect.

Frequently Asked Questions

Juzina contains sitagliptin, a DPP‑4 inhibitor indicated for the treatment of type 2 diabetes mellitus. It helps lower blood glucose levels by improving insulin secretion and reducing glucagon release when used together with diet and exercise.

Sitagliptin blocks the enzyme dipeptidyl peptidase‑4, which normally breaks down the incretin hormones GLP‑1 and GIP. By preserving these hormones, the drug enhances glucose‑dependent insulin release and suppresses glucagon, leading to better control of fasting and post‑prandial blood sugar.

The appropriate dose of Juzina is determined by a qualified prescriber based on the individual’s clinical condition, renal function, and concomitant therapies. Patients should follow the dosing instructions provided by their healthcare professional.

Safety of sitagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by the prescribing clinician.

To order Juzina, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Juzina (sitagliptin) belongs to the DPP‑4 inhibitor class, which differs from sulfonylureas, metformin, or insulin. It offers glucose‑dependent action with a low risk of hypoglycaemia when used alone, and can be combined with other agents for additive effect, providing an alternative for patients who cannot tolerate other classes.

Store Juzina at ambient temperature, preferably below 25 °C, in its original container. Protect the product from moisture, direct sunlight, and extreme heat to maintain its stability throughout its shelf life.

Juzina is taken orally, usually once daily, with or without food, as directed by a healthcare professional. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious adverse events linked to Juzina include pancreatitis, severe allergic reactions such as anaphylaxis, and rare skin conditions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or signs of an allergic response.

Juzina should be avoided in individuals with known hypersensitivity to sitagliptin or any component of the formulation. Caution is also advised for patients with severe renal impairment, uncontrolled liver disease, or those who are pregnant or breastfeeding unless the prescriber determines that benefits outweigh risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sitagliptin Hydrochloride Monohydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT